Efinopegdutide

Subcutaneous injection once weekly. Clinical trials used target doses of 5 mg, 7.5 mg, and 10 mg, titrated over ~8 weeks. The 10 mg dose showed the greatest efficacy for both weight loss and liver fat reduction. GI adverse events (nausea, vomiting, diarrhea) occurred in up to 89% of participants at higher doses. Currently in Phase 2b trials for MASH/NAFLD.

Activates the GLP-1 receptor to promote insulin secretion, suppress appetite, slow gastric emptying, and reduce food intake.

Activates the glucagon receptor to increase energy expenditure, promote hepatic fat oxidation, and reduce liver fat content. The balanced dual agonism prevents glucagon-mediated hyperglycemia.

Conjugation to human IgG4 Fc region extends the pharmacokinetic half-life, enabling once-weekly dosing.

In Phase IIa trials, efinopegdutide 10 mg reduced liver fat by 72.7% vs 42.3% for semaglutide 1 mg at 24 weeks. Granted FDA fast track designation for MASH.

In people with obesity without diabetes, placebo-subtracted weight loss after 26 weeks was -6.8% (5 mg), -8.1% (7.5 mg), and -10.0% (10 mg), compared to -5.8% for liraglutide 3.0 mg.

Dual GLP-1/glucagon receptor agonism provides balanced metabolic effects that prevent glucagon-mediated hyperglycemia while improving insulin sensitivity.

Study 40489581

Study 39776746

Study 39028914